Effects of a pro‐resolving drug in COVID‐19: preclinical studies to a randomized, placebo‐controlled, phase Ib/IIa trial in hospitalized patients
Treatment with AP1189 was associated with less disease caused by beta-coronavirus infection both in mice and in humans. This is the first demonstration of the effects of a pro-resolving molecule in the context of severe infection in humans.
Authors
- Pedro R. J. Almeida
- Mauro Perretti (ORCID: https://orcid.org/0000-0003-2068-3331)
- Ângela Vieira Serufo (ORCID: https://orcid.org/0000-0001-9984-0648)
- Carolina Braga de Resende (ORCID: https://orcid.org/0000-0002-2343-6013)
- Celso Martins Queiroz‐Junior (ORCID: https://orcid.org/0000-0002-7884-7709)
- Mauro Martins Teixeira (ORCID: https://orcid.org/0000-0002-6944-3008)
- Renata Marcondes
- Renan P. Souza (ORCID: https://orcid.org/0000-0002-9479-4432)
- Danielle Cunha Teixeira
- Fernanda L. Tana (ORCID: https://orcid.org/0000-0002-4692-0836)
- Vivian Vasconcelos Costa (ORCID: https://orcid.org/0000-0002-0175-642X)
- Felipe Rocha da Silva Santos (ORCID: https://orcid.org/0000-0002-8392-1467)
- Bárbara Luísa Vieira da Silva
- Alexandre M. Periard
- Larissa B. Milhorato
- Katlen M. M. Alcantara
- Thomas E. N. Jonassen
- Talita Cristina Martins Fonseca
Institutions
- Universidade Federal de Minas Gerais (BR)
- University of Copenhagen (DK)
- Queen Mary University of London (GB)
- William Harvey Research Institute (GB)
- Fundação Hospitalar do Estado de Minas Gerais (BR)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1111/bph.17322
- Citations
- 4
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.56
Funders
- Queen Mary University of London
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- Universidade Federal de Minas Gerais